Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Rigel Pharmaceuticals Inc

RIGL ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$48.50

▼ -1.86%

Market Cap $905.97M · Vol 74.71K

Key Metrics

P/E Ratio

3.02

FWD: 11.92

Market Cap

$905.97M

Small Cap

Div Yield

N/A

EPS Growth

-54.71%

YoY

RSI (14)

69.87

Momentum

Beta

1.19

vs Market

52W High

$51.96

4.89% below

52W Low

$25.00

97.68% above

Volume

74.71K

Avg 106.73K

P/B

2.00

Price-to-book

ROE

185.94%

Return on equity

Free Float

96.58%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Rigel Pharmaceuticals Inc (RIGL) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RIGL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.50%

+29.58%

+60.07%

+46.88%

YTD

+13.24%

+22.44%

+311.02%

+19.75%

Financials & Valuation

TTM · Annual

Total Revenue	$294.28M
Net Income	$367.02M
Revenue Growth (YoY)	-22.60%
Gross Margin	93.33%
Operating Margin	42.63%
Net Profit Margin	124.72%
ROE	185.94%
ROA · ROIC	35.96% · 153.56%

P/E Ratio	3.02
Forward P/E (FY1)	11.92
PEG Ratio	0.00
P/S	2.74
P/B	2.00
P/FCF	10.67
EPS Growth	-54.71%
Outstanding Shares	18.68M

Technical Indicators

50-Day SMA	$41.63
200-Day SMA	$36.36
RSI (14)	69.87
Beta	1.19
52-Week High	$51.96
52-Week Low	$25.00

Volume Today	74.71K
Avg Daily Volume (30D)	106.73K
Relative Volume	0.70x
Volatility (10D)	32.45
Volatility (30D)	42.66
Free Float	96.58%

Analyst Consensus

BUY

Current Price $48.50

Mean Target $63.00

52W Low$25.00 52W High$51.96

Current

Target

$25.00 $51.96

Current Analyst target

+29.90% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SD33Z0

ISINUS7665597024

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -0.04% JNJ Johnson & Johnson +1.17% ABBV Abbvie Inc -0.58% NVS Novartis AG +0.39% NOVN.S Novartis AG +0.00%

Company Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.